Wellington Management Group LLP 13D and 13G filings for Aclaris Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-12-11 09:36 am Sale | 2023-11-30 | 13G | Aclaris Therapeutics, Inc. ACRS | Wellington Management Group LLP | 0 0.000% | -7,372,601 (Position Closed) | Filing |
| 2023-04-10 09:06 am Purchase | 2023-03-31 | 13G | Aclaris Therapeutics, Inc. ACRS | Wellington Management Group LLP | 7,372,601 11.050% | 1,888,588 (+34.44%) | Filing |
| 2023-02-06 2:43 pm Sale | 2022-12-30 | 13G | Aclaris Therapeutics, Inc. ACRS | Wellington Management Group LLP | 5,484,013 8.220% | -55,255 (-1.00%) | Filing |
| 2022-02-04 09:12 am Purchase | 2021-12-31 | 13G | Aclaris Therapeutics, Inc. ACRS | Wellington Management Group LLP | 5,539,268 9.050% | 5,539,268 (New Position) | Filing |